文献速递其他结缔组织病

肌炎作为癌症免疫检查点阻断治疗的不良事件

Myositis as an adverse event of immune checkpoint blockade for cancer therapy.
PubMed 文献 · Semin Arthritis Rheum · 2018-05-18

该研究报告了2004年1月至2016年9月在得克萨斯大学MD安德森癌症中心接受免疫检查点抑制剂(ICI)治疗的6例新发肌炎患者。从首次输注到发生新发肌炎的中位时间为5.4周(范围2.1-17.1周),所有患者肌酸激酶升高(514-13710 U/L),2例发生横纹肌溶解,其中1例合并心肌炎。作者认为这些初步数据提示肌炎可在ICI治疗开始后早期发生并伴严重不良结局。

要点

  • 接受ICI治疗的患者可在首次输注后中位5.4周(范围2.1-17.1周)发生新发肌炎。
  • 所有肌炎患者肌酸激酶升高,范围514-13710 U/L,2例发生横纹肌溶解,其中1例合并心肌炎。
  • 5例接受1-2mg/kg糖皮质激素治疗,1例接受非甾体抗炎药,2例因癌症进展死亡。

核心结论

  • 作者报告了ICI治疗后新发肌炎的若干病例,初步数据提示肌炎可在ICI治疗开始后早期发生并伴严重不良结局。

研究设计与样本

  • 在得克萨斯大学MD安德森癌症中心识别2004年1月至2016年9月期间接受ICI治疗并发生肌炎的患者,报告6例新发肌炎患者。

主要发现

  • 6例新发肌炎患者平均年龄64.3岁,5例为男性,癌症类型包括黑色素瘤、尿路上皮癌、肾细胞癌和前列腺癌。
  • ICI方案包括单药伊匹木单抗(n=1)、帕博利珠单抗(n=1)、阿替利珠单抗(n=1),以及纳武利尤单抗联合伊匹木单抗(n=3)。
  • 从首次输注到发生新发肌炎的中位时间为5.4周(范围2.1-17.1周),所有患者肌酸激酶升高,范围514-13710 U/L。
  • 2例发生横纹肌溶解,其中1例合并心肌炎;5例接受1-2mg/kg糖皮质激素治疗,1例接受非甾体抗炎药。
  • 2例肌炎患者因癌症进展死亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Immune checkpoint inhibitors (ICIs) can successfully treat cancer, but their use can be hindered by serious immune-related adverse events. We report six patients receiving ICIs who presented with de novo myositis. METHODS: We identified patients with myositis who were receiving ICIs between January 2004 and September 2016 at The University of Texas MD Anderson Cancer Center. RESULTS: Six patients developed de novo myositis. The mean age was 64.3 years and five patients were male. Cancer types included melanoma, urothelial carcinoma, renal cell carcinoma, and prostate cancer. ICI regimens included single-agent ipilimumab (n = 1), pembrolizumab (n = 1), or atezolizumab (n = 1); nivolumab and ipilimumab (n = 3). The median time to development of de novo myositis from first infusion was 5.4 weeks (range: 2.1-17.1 weeks). All patients with myositis had elevated levels of creatinine kinase, ranging from 514 to 13,710U/L. Two of them developed rhabdomyolysis, one with concurrent myocarditis. Five patients were treated with 1-2mg/kg corticosteroids, with variable response rates; one patient received nonsteroidal anti-inflammatory drugs. Two patients with myositis died as a result of cancer progression. CONCLUSION: We found several occurrences of de novo myositis following ICI therapy. These preliminary data suggest that myositis can occur early after onset of ICI therapy with serious adverse outcomes.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Shah M, Tayar JH, Abdel-Wahab N, et al. Myositis as an adverse event of immune checkpoint blockade for cancer therapy. Semin Arthritis Rheum. 2018. PMID: 29909921. doi:10.1016/j.semarthrit.2018.05.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。